Attached files
file | filename |
---|---|
EX-99.1 - ORAMED PHARMACEUTICALS INC. | v206565_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): December 27, 2010
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
7.01
|
REGULATION
FD DISCLOSURE
|
On
December 23, 2010, Oramed Pharmaceuticals Inc. (the “Company”) issued a press
release reporting that its wholly owned Israeli subsidiary, Oramed Ltd, was
awarded a government grant amounting to a total net of 2.9 million NIS
($807,000), from the Office of the Chief Scientist (OCS) at the Ministry of
Industry, Trade and Labor of Israel. This grant was awarded as government
participation in research and development expenses for the period July 2010 to
June 2011, and it is subject to return according to the terms determined by the
OCS.
A copy of
the press release is attached to this Current Report on Form 8-K as Exhibit 99.1
and is incorporated herein by reference.
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
(d)
|
Exhibits
|
|
99.1
|
Press
Release dated December 23,
2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
ORAMED
PHARMACEUTICALS INC.
|
||
Dated:
December 27, 2010
|
||
By:
|
/s/
Nadav Kidron
|
|
Nadav
Kidron
|
||
President,
CEO and Director
|
Exhibit
Index
Exhibit
Number
|
Description
|
|
99.1
|
Press
Release dated December 23,
2010.
|